Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis

- Multiple Sclerosis
- Completed

Study Title: Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to ClinicFemale, Maley Definite Multiple Sclerosis of Subjects Presenting With ClinicFemale, Maley Isolated Syndrome

Teva Identifier: GA 9010

ClinicalTrials.gov Identifier: NCT00666224

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate (DB)|Drug: Placebo | Drug: Glatiramer Acetate (OL)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 45 Years

Trial Duration: 01/01/2004 - 06/01/2010

Phase: Phase 3

Study Type

Interventional